A5053848207- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- Histone Deacetylase Inhibitors Research
- Colorectal Cancer Surgical Treatments
- Economic and Financial Impacts of Cancer
- Palliative Care and End-of-Life Issues
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Screening and Detection
- Frailty in Older Adults
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
- Clinical practice guidelines implementation
- Nutrition and Health in Aging
- Electronic Health Records Systems
- Global Cancer Incidence and Screening
- Patient-Provider Communication in Healthcare
- Chemotherapy-related skin toxicity
- Health Systems, Economic Evaluations, Quality of Life
Dana-Farber Cancer Institute
2016-2025
Harvard University
2013-2025
Brigham and Women's Hospital
2011-2024
Massachusetts General Hospital
2012-2023
University of Ottawa
2023
Dana-Farber Brigham Cancer Center
2019-2022
Berry (United States)
2022
CancerCare
2020
Ollscoil na Gaillimhe – University of Galway
2019
Sage Bionetworks
2017
Abstract Author Summary Background. Autophagy is a catabolic pathway that permits cells to recycle intracellular macromolecules, and its inhibition reduces pancreatic cancer growth in model systems. We evaluated hydoxychloroquine (HCQ), an inhibitor of autophagy, patients with analyzed pharmacodynamic markers treated mice. Methods. Patients previously metastatic were administered HCQ at 400 mg (n = 10) or 600 twice daily. The primary endpoint was 2-month progression-free survival (PFS)....
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA patients with advanced PDAC. Therapeutically genomic alterations were identified 48% (34/71) pathogenic/likely pathogenic germline 18% (13/71) of patients. Overall, 30% (21/71) enrolled experienced change management as result data. Twenty-six had and/or...
Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown.
Alterations in the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway are major drivers colorectal carcinogenesis. In cancer, BRAF mutation is associated with microsatellite instability (MSI), and typically predicts inferior prognosis. We examined effect of on survival treatment efficacy patients stage III colon cancer.We assessed status c.1799T>A (p.V600E) MSI 506 cancer enrolled a randomized adjuvant chemotherapy trial [5-fluorouracil leucovorin (FU/LV) vs. irinotecan (CPT11), FU LV (IFL); CALGB...
Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) are now standard. We examined the impact age on recurrence mortality after these newer options. Patients Methods analyzed 11,953 < 70 2,575 ≥ years seven trials comparing IV FU fluoropyrimidines (capecitabine, uracil, or tegafur) combinations oxaliplatin...
<h3>Importance</h3> In observational studies, higher plasma 25-hydroxyvitamin D (25[OH]D) levels have been associated with improved survival in metastatic colorectal cancer (CRC). <h3>Objective</h3> To determine if high-dose vitamin D<sub>3</sub>added to standard chemotherapy improves outcomes patients CRC. <h3>Design, Setting, and Participants</h3> Double-blind phase 2 randomized clinical trial of 139 advanced or CRC conducted at 11 US academic community centers from March 2012 through...
Abstract While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in V600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 trial of combined PD-1, sparatlizumab (PDR001), dabrafenib trametinib 37 patients CRC. The primary end point was overall rate, secondary points were...
ABSTRACT Background Insomnia is the most common sleep disturbance among cancer patients undergoing active treatment. If untreated, it associated with significant physical and psychological health consequences. Prior efforts to determine insomnia prevalence correlates have primarily assessed in clinical trials, limited disease groups, excluding important patient subgroups. These findings are likely be influenced by research participation effects, which could bias outcomes. We sought address...
228 Background: Activation of VEGFR2 and c-MET has been implicated in driving growth neuroendocrine tumors (NET); additionally, expression associated with shorter survival. Cabozantinib inhibits c-MET. We performed a two-cohort phase II study to evaluate the efficacy cabozantinib patients (pts) advanced carcinoid or pNET (NCT01466036). Methods: Pts progressive, well differentiated, grade 1-2 were enrolled parallel cohorts treated 60 mg po qd . There was no limit prior therapy. restaged every...
Collecting patient-reported outcomes (PROs) can improve symptom control and quality of life, enhance doctor-patient communication, reduce acute care needs for patients with cancer. Digital solutions facilitate PRO collection, but without robust electronic health record (EHR) integration, effective deployment be hampered by low patient clinician engagement high development costs. The important components digital platforms have been defined, procedures implementing integrated are not readily...
Abstract Background. The Cancer-Specific Geriatric Assessment (CSGA) is a primarily self-administered paper survey of validated measures. Methods. We developed and tested the feasibility computer-based CSGA in patients ≥70 years age who were receiving treatment for gastrointestinal malignancies at Dana-Farber Cancer Institute. From December 2009 to June 2011, invited complete baseline (start new treatment) follow-up (at first 4 months later or within weeks completing treatment). Feasibility...
We conducted a single-arm phase II study of cediranib, pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC).Patients histologically confirmed measurable HCC and adequate hematologic, hepatic, renal functions received cediranib 30-mg orally once daily (4 weeks/cycle). The primary endpoint was progression-free survival (PFS) rate at 3 months. Other endpoints included response rates, overall (OS), pharmacokinetics (PK), biomarkers for cediranib.Cediranib...
The incidence of young-onset colorectal cancer (yoCRC) is increasing. It unknown if there are survival differences between young and older patients with metastatic (mCRC).We studied the association age in 2326 mCRC enrolled Cancer Leukemia Group B SWOG 80405 trial, a multicenter, randomized trial first-line chemotherapy plus biologics. primary secondary outcomes this study were overall (OS) progression-free (PFS), respectively, which assessed by Kaplan-Meier method compared among younger vs...
Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous carcinoma and biomarkers predictive of response are greatly needed. This multicenter phase II clinical trial (NCT02919969) enrolled metastatic or locally advanced incurable (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint the was objective rate (ORR). Exploratory objectives included analysis potential including assessment...
Abstract Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Herein, we report clinical and translational results from a phase Ib trial testing whether IL1β blockade pancreatic cancer would alleviate myeloid immunosuppression reveal antitumor T-cell responses to PD1 blockade. Patients with treatment-naïve advanced ductal adenocarcinoma (n = 10) were treated canakinumab, high-affinity monoclonal...
Abstract Objectives Well-differentiated neuroendocrine tumors (NET) are highly vascular characterized by their expression of endothelial growth factor (VEGF). This trial investigated the activity ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits VEGF, in combination with somatostatin analog therapy patients (pts) advanced extra-pancreatic NET. Methods We conducted single-arm phase II enrolling pts advanced, progressive Patients were treated ramucirumab 8...
This cohort study evaluates the responsiveness of a quality-of-life questionnaire among patients with head and neck cancer before after surgery, stratified by oral cavity resection or dissection.
Methods of integrating qualitative data across diverse studies and within multi-site research consortia are less developed than those for quantitative data. The development ofsuchmethods is essential to support the exchange needed cross-study inquiry given increasing emphasis on sharing open science. We describe methods integration National Cancer Institute's Improving Management symPtoms During And following Treatment (IMPACT) Consortium funded by MoonshotSM. Data collection analysis were...
Abstract Background People with advanced ovarian cancer and their caregivers report unmet supportive care needs. We developed a Collaborative Agenda-Setting Intervention (CASI) to elicit patients’ caregivers’ needs through the patient portal before clinic visit communicate these clinicians using electronic health record. Objective aimed assess usability acceptability of CASI identify barriers facilitators its implementation. Methods recruited English- Spanish-speaking patients, caregivers,...
Abstract BACKGROUND: Cigarette smoking has been shown to increase the risk of developing colorectal cancer, particularly early in life. Little is known about impact tobacco use on colon cancer recurrence among survivors. METHODS: The authors prospectively collected lifetime history from stage III patients enrolled a phase 3 trial via self‐report questionnaires during and 6 months after completion adjuvant chemotherapy. Smoking status was defined as never, current, or past. Lifetime...
Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer. We examined associations oncogene mutation with relapse, survival, treatment efficacy 627 stage III colon carcinoma case subjects within a randomized adjuvant chemotherapy trial (5-fluorouracil leucovorin [FU/LV] vs irinotecan [CPT11], fluorouracil [IFL];...